Wave Life Sciences Ltd.
WVE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $108 | $113 | $4 | $41 |
| % Growth | -4.4% | 3,005.1% | -91.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $108 | $113 | $4 | $41 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $160 | $130 | $116 | $122 |
| G&A Expenses | $59 | $51 | $51 | $46 |
| SG&A Expenses | $59 | $51 | $51 | $46 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $219 | $181 | $166 | $168 |
| Operating Income | -$110 | -$68 | -$163 | -$127 |
| % Margin | -101.9% | -60% | -4,459.3% | -310.1% |
| Other Income/Exp. Net | $13 | $10 | $2 | $5 |
| Pre-Tax Income | -$97 | -$58 | -$161 | -$122 |
| Tax Expense | $0 | -$1 | $1 | -$0 |
| Net Income | -$97 | -$58 | -$162 | -$122 |
| % Margin | -89.6% | -50.8% | -4,434.7% | -298.4% |
| EPS | -0.7 | -0.54 | -2.05 | -2.36 |
| % Growth | -29.6% | 73.7% | 13.1% | – |
| EPS Diluted | -0.7 | -0.54 | -2.05 | -2.36 |
| Weighted Avg Shares Out | 138 | 106 | 79 | 52 |
| Weighted Avg Shares Out Dil | 138 | 106 | 79 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | – |
| Depreciation & Amortization | $9 | $9 | $10 | $10 |
| EBITDA | -$102 | -$59 | -$153 | -$117 |
| % Margin | -93.9% | -51.9% | -4,182.1% | -286.1% |